Dr. Saloni Wagh, Director of Supriya Lifescience, has lauded the Union Budget 2024-25 as a significant step towards realizing the vision of a developed India. She highlighted the budget’s focus on key areas such as employment, skill development, MSME growth, and the upliftment of the middle class.
“This budget is a clear roadmap to a Vikasit Bharat, with a strong emphasis on the welfare of the poor, women, youth, and farmers,” Dr. Wagh stated. “The allocation of substantial funds for employment, skill development, and education is a commendable move that will create a skilled workforce, essential for driving innovation and growth.”
Dr. Wagh particularly appreciated the full exemption of basic customs duties on three cancer treatment medicines, emphasizing its positive impact on both the pharmaceutical sector and cancer patients. She also expressed optimism about India’s burgeoning pharmaceutical industry, stating that with the ₹2,143 crore allocation under the PLI scheme, India is poised to emerge as a global leader in pharmaceuticals.
“The budget’s emphasis on innovation, R&D, and education is crucial for India to become a global manufacturing hub,” she added. “These initiatives will foster a robust research ecosystem, enhance education quality, and create a skilled workforce capable of driving technological advancements.”
Dr. Wagh concluded by stating that the budget’s measures are aligned with the government’s ambitious target of achieving a $5 trillion GDP in three years and a $7 trillion economy by 2030.